JOHANNESBURG, Tuesday 20th January: The Treatment Action Campaign (TAC), Doctors Without Borders (MSF) and SECTION27 applaud India’s decision to reject a patent application on sofosbuvir, an important new treatment for…
SECTION27 and the TAC have released a statement highlighting recent improprieties by pharmaceutical companies and calling for more vigilance from all stakeholders in ensuring that we meet the goals of the National Strategic Plan on HIV and AIDS, TB and STIs.
The Treatment Action Campaign (TAC), SECTION27 and Médecins Sans Frontières / Doctors Without Borders (MSF) South Africa voice support for their partners across the world opposing provisions in a proposed free trade agreement (FTA) between India and the European Union (EU) that threaten the sustainable supply of affordable medicines to millions of people in the developing world.
India’s Department of Industrial Policy and Promotion (DIPP) recently published a discussion paper on compulsory licensing and made a call for interested parties to make submissions. On 7 October 2010, SECTION27 made a submission.
Letter to the High Commissioner for India to South Africa: Our concerns regarding Indian trade negotiations with EU.
This letter explains that the prospect of making new ARVs available in South Africa at affordable prices is under threat because of events unfolding in India. In particular, pressure is being applied by the European Union on the Indian government to sign a bilateral trade agreement that will stifle competition on essential medicines still under patent.